Tenax Therapeutics Inc, formerly Oxygen Biotherapeutics, Inc., is engaged in the business of developing biotechnology products with a focus on oxygen delivery to specific target tissues. The Company is developing Oxycyte, a systemic perfluorocarbon (PFC). In addition, it has developed a family of perfluorocarbon-based oxygen carriers for use in personal care, topical wound healing, and other topical indications. The Company also plans to focus on developing its topical products: Dermacyte and Wundecyte. It also has under development Vitavent, an oxygen exchange fluid for facilitating the treatment of lung conditions, and the Company has rights to a biosensor implant product that uses an enzyme process for measuring the glucose level in subcutaneous fluid. The Company intends to develop additional clinical research protocols and conduct proof-of-concept studies for topical indications, such as the treatment of acne, rosacea, pruritis, psoriasis, and dermatitis.